Crinetics Pharmaceuticals, Inc.
https://www.crinetics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Crinetics Pharmaceuticals, Inc.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Crinetics May Have Drug Profile To Take Leading Position In Acromegaly
Reporting a second positive Phase III trial for oral paltusotine, Crinetics plans an NDA later this year to position its drug against competing injectable somatostatin analogs.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Unpartnered Assets To Watch In 2024
Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice